Security record · archived quarter
CTMX
CytomX Therapeutics, Inc. · Healthcare · Biotechnology
7Tracked holders
0Δ holders
9.00MShares held
$9.27MReported value
+1New positions
−1Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +11 | 136.41M | $511.64M | +18 | −7 |
| Q1 2026 | 64 | +15 | 111.19M | $522.57M | +20 | −5 |
| Q4 2025 | 49 | -1 | 71.30M | $303.77M | — | −1 |
| Q3 2025 | 14 | 0 | 41.38M | $131.99M | — | — |
| Q2 2025 | 11 | 0 | 36.17M | $82.10M | — | — |
| Q1 2025 | 8 | +1 | 8.01M | $5.09M | +1 | — |
| Q4 2024 | 7 | 0 | 9.00M | $9.27M | +1 | −1 |
| Q3 2024 | 6 | 0 | 8.17M | $9.64M | — | — |
| Q2 2024 | 6 | — | 7.95M | $9.70M | — | — |
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 3.22M | +25.8% | $3.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 2.65M | New | $2.73M | 0.0% | New | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 1.35M | +32.7% | $1.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 815.64K | +1.5% | $840,331 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 815.64K | +1.5% | $840,331 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 322.31K | +1.6% | $331,980 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 320.77K | -32.0% | $330,390 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 320.04K | — | $329,644 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $2.73M | 0.0% |
Exited
| Adage Capital Partners | $3.54M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 178 holders, 193.14M shares, $906.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API